Business Wire
14 Jun 2026, 08:00 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
1 claim · each scored for market impact
OM Pharma is unveiling the largest multi-country real-world evidence study on Broncho Vaxom (OM 85) for respiratory tract infection prevention at EAACI 2026. — Positive real-world evidence can expand market adoption and support pricing/reimbursement for the drug, though the impact is limited to a specific product line.
+0.30Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Continue reading
6 related stories
Top 1 mover · tap to explore
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
CNBC
16h ago
